'For me, the biggest thing I had to learn was listening'
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about ...
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
When we talk about genomics hubs, then usually we’d be talking about Oxbridge, Boston or Silicon Valley thanks to success stories like 10x Genomics, Illumina or Solexa. However, as the technology needed to conduct genomic R&D becomes more accessible
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background
To achieve the WHO's ambitious aim that no woman should die of cervical cancer by 2030 it will take a huge, global effort from companies around the world. Luckily, there is a global community of life sciences companies to help achieve that aim.
Billions of dollars have been pumped into medicinal cannabis. It’s popular with patients. The public’s perceptions are changing (for the better) and the competition isn’t nearly as tough as other markets in pharmaceuticals.
Decentralised, virtual, home, remote… whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.
Connectivity is the future for labs, bringing countless benefits. Check out the forward-thinking companies leading this technology trend.
Analytical instruments are crucial to manufacturing and R&D, helping analyse materials to establish their composition. This data makes it easier to simplify processes, increase efficiency and productivity.
Heading into the proactive world of personalised care, data insights are providing us with more effective, targeted and preventative treatments for patients.
Returning from CPhI 2019, in Frankfurt, the words of Eric Langer, President of Bioplan Associates, have stuck with me. Forget the innovation, are biosimilars the real 'workhorse' carrying biopharma to bigger and better things?
Reported to correct 89% of pathogenic human gene variants, prime gene editing has the potential to target over 75,000 different mutations in treatment.
Pharma packaging is in transition. Companies are now pushing boundaries, furthering their offerings and innovating to be seen as true healthcare partners.
Our specialist in lab equipment and technology, Lucy Smith, is looking to get in touch with senior leaders in the life science space to learn more about connectivity.